These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32984034)

  • 1. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
    Tian Z; Niu X; Yao W
    Front Oncol; 2020; 10():1642. PubMed ID: 32984034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
    Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update.
    Greenfield EM; Collier CD; Getty PJ
    Adv Exp Med Biol; 2020; 1258():141-155. PubMed ID: 32767239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives.
    Liu J; Xia S; Zhang B; Mohammed DM; Yang X; Zhu Y; Jiang X
    Discov Oncol; 2024 Jul; 15(1):259. PubMed ID: 38960980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.
    Rettew AN; Young ED; Lev DC; Kleinerman ES; Abdul-Karim FW; Getty PJ; Greenfield EM
    Oncogenesis; 2012 Nov; 1(11):e34. PubMed ID: 23552467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
    Fleuren EDG; Vlenterie M; van der Graaf WTA
    Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
    Huang L; Fu L
    Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
    Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
    J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
    Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
    Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
    de Rosamel L; Blanc JF
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinases and targeted cancer therapeutics.
    Takeuchi K; Ito F
    Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
    Demetri GD
    Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma.
    Chaiyawat P; Klangjorhor J; Settakorn J; Champattanachai V; Phanphaisarn A; Teeyakasem P; Svasti J; Pruksakorn D
    Transl Oncol; 2017 Oct; 10(5):846-853. PubMed ID: 28881260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
    Gudernova I; Balek L; Varecha M; Kucerova JF; Kunova Bosakova M; Fafilek B; Palusova V; Uldrijan S; Trantirek L; Krejci P
    Oncotarget; 2017 Dec; 8(65):109319-109331. PubMed ID: 29312610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
    Grüllich C
    Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.
    Qian Y; Yu L; Zhang XH; Yuan ZQ; Zhao P; Sun LN; Wang YQ
    Curr Drug Metab; 2018; 19(14):1168-1181. PubMed ID: 29956623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma.
    Chen C; Shi Q; Xu J; Ren T; Huang Y; Guo W
    Cell Death Discov; 2022 Dec; 8(1):488. PubMed ID: 36509754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming therapeutic failure in osteosarcoma
    Li X; Wang L; Wang L; Yu J; Lu G; Zhao W; Miao C; Zou C; Wu J
    Biomater Sci; 2020 Oct; 8(21):5888-5899. PubMed ID: 33001086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.